{"id":7297,"date":"2024-11-25T08:00:00","date_gmt":"2024-11-25T07:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/"},"modified":"2024-11-25T08:00:00","modified_gmt":"2024-11-25T07:00:00","slug":"nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/","title":{"rendered":"Nanexa bjuder in till en webcast f\u00f6r att presentera de positiva kliniska data fr\u00e5n en-m\u00e5naders dep\u00e5 av GLP-1, liraglutid-projektet NEX-22 som publicerades i fredags"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Med h\u00e4nvisning till de kliniska resultaten som presenterades i fredags bjuder Nanexa in till en webcast som s\u00e4nds via Infront Direkt Studios kl. 14.00 idag, m\u00e5ndagen den 25 november.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Styrelseordf\u00f6rande Dr. G\u00f6ran Ando, VD David Westberg och Aff\u00e4rsutvecklingsansvarig Otto Skolling kommer att presentera resultaten samt en \u00f6versikt av GLP-1-segmentet och planerna fram\u00e5t.<br \/>\u201dDessa kliniska resultat s\u00e4tter oss i en helt ny, mycket sp\u00e4nnande situation med potential att f\u00f6r\u00e4ndra behandlingsregimen f\u00f6r typ 2-diabetes och fetma till mindre frekventa behandlingar\u201d, s\u00e4ger David Westberg, VD Nanexa.<\/p>\n<p>Kommentaren kommer att finnas tillg\u00e4nglig <a href=\"https:\/\/eur01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fyoutube.com%2Flive%2FJdsHopoAR6U&amp;data=05|02|maria.medeen%40nanexa.se|5c8672660c1142af95e108dd088eca54|cf2057b571ae407dac1e06fc7f9e6904|0|0|638676131516307079|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&amp;sdata=qdeQ0LVKReoq3C0h8NEu%2BFpwQPesZfuRsWWsE%2FEmlTc%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">h\u00e4r.<\/a><br \/>Det kommer att finnas m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chatt.<\/p>\n<p>Kommentaren kommer \u00e4ven att publiceras p\u00e5 Nanexas hemsida i efterhand.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/0f547eb5-35ef-4763-8cbe-7be38112acef\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa bjuder in till en webcast f\u00f6r att presentera de positiva kliniska data fr\u00e5n en-m\u00e5naders dep\u00e5 av GLP-1, liraglutid-projektet NEX-22 som publicerades i fredags<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Med h\u00e4nvisning till de kliniska resultaten som presenterades i fredags bjuder Nanexa in till en webcast som s\u00e4nds via Infront Direkt Studios kl. 14.00 idag, m\u00e5ndagen den 25 november.<\/p>\n","protected":false},"template":"","class_list":["post-7297","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa bjuder in till en webcast f\u00f6r att presentera de positiva kliniska data fr\u00e5n en-m\u00e5naders dep\u00e5 av GLP-1, liraglutid-projektet NEX-22 som publicerades i fredags - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa bjuder in till en webcast f\u00f6r att presentera de positiva kliniska data fr\u00e5n en-m\u00e5naders dep\u00e5 av GLP-1, liraglutid-projektet NEX-22 som publicerades i fredags - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Med h\u00e4nvisning till de kliniska resultaten som presenterades i fredags bjuder Nanexa in till en webcast som s\u00e4nds via Infront Direkt Studios kl. 14.00 idag, m\u00e5ndagen den 25 november.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\\\/\",\"name\":\"Nanexa bjuder in till en webcast f\u00f6r att presentera de positiva kliniska data fr\u00e5n en-m\u00e5naders dep\u00e5 av GLP-1, liraglutid-projektet NEX-22 som publicerades i fredags - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-11-25T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa bjuder in till en webcast f\u00f6r att presentera de positiva kliniska data fr\u00e5n en-m\u00e5naders dep\u00e5 av GLP-1, liraglutid-projektet NEX-22 som publicerades i fredags\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa bjuder in till en webcast f\u00f6r att presentera de positiva kliniska data fr\u00e5n en-m\u00e5naders dep\u00e5 av GLP-1, liraglutid-projektet NEX-22 som publicerades i fredags - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa bjuder in till en webcast f\u00f6r att presentera de positiva kliniska data fr\u00e5n en-m\u00e5naders dep\u00e5 av GLP-1, liraglutid-projektet NEX-22 som publicerades i fredags - Nanexa AB","og_description":"Med h\u00e4nvisning till de kliniska resultaten som presenterades i fredags bjuder Nanexa in till en webcast som s\u00e4nds via Infront Direkt Studios kl. 14.00 idag, m\u00e5ndagen den 25 november.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/","name":"Nanexa bjuder in till en webcast f\u00f6r att presentera de positiva kliniska data fr\u00e5n en-m\u00e5naders dep\u00e5 av GLP-1, liraglutid-projektet NEX-22 som publicerades i fredags - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-11-25T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-bjuder-in-till-en-webcast-for-att-presentera-de-positiva-kliniska-data-fran-en-manaders-depa-av-glp-1-liraglutid-projektet-nex-22-som-publicerades-i-fredags\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa bjuder in till en webcast f\u00f6r att presentera de positiva kliniska data fr\u00e5n en-m\u00e5naders dep\u00e5 av GLP-1, liraglutid-projektet NEX-22 som publicerades i fredags"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}